Nutcracker Therapeutics, Inc.

Unlocking the Potential of RNA Through High Technology

Nutcracker’s ACORN Platform uses proprietary hardware and software combined with innovations in mRNA biochemistry and nanoparticle delivery to produce optimized mRNA therapies on biochips.

News

Nutcracker Therapeutics Strengthens Leadership Team with Appointment of Madhavan Balachandran as Chief Operating Officer

Emeryville, Calif. – September 23, 2020 – Nutcracker Therapeutics, Inc., a company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, today announced the appointment of Madhavan (“Madhu”) Balachandran, former executive vice president Read more…

News

Nutcracker Therapeutics Announces $60 Million Series B Financing to Advance mRNA Therapeutics Produced on Transformational Biochip-Based ACORN Platform

Emeryville, Calif. – September 23, 2020 Financing led by ARCH Venture Partners Company aims to efficiently develop, manufacture and deliver mRNA medicines to patients worldwide using its proprietary push-button “GMP-in-a-box” system Company will initially focus Read more…

Transformational mRNA Therapeutics at the Push of a Button

Unlocking the Potential of RNA Through High Technology

Nutcracker’s ACORN Platform uses proprietary hardware and software combined with innovations in mRNA biochemistry and nanoparticle delivery to produce optimized mRNA therapies on biochips.

Push Button Operation

Rapid Cycle Times

GMP-in-the-Box

Novel Delivery Vehicles

For the Benefit of Patients

News

News

Nutcracker Therapeutics Strengthens Leadership Team with Appointment of Madhavan Balachandran as Chief Operating Officer

News

Nutcracker Therapeutics Announces $60 Million Series B Financing to Advance mRNA Therapeutics Produced on Transformational Biochip-Based ACORN Platform